Revelation Biosciences, Inc. (NasdaqCM: REVB)
Health Care · Biotechnology · US
$1.00
-4.67% today · -90.3% 1Y
Revelation Biosciences, Inc. (NasdaqCM: REVB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.18M and employs 8 people.
Over the last twelve months the share price has lost 90.3%, trading between 0.88 and 11.72.
Tweenvest scores Revelation Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
REVB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.18M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -8.31
- Dividend yield
- —
- Beta (5Y)
- -0.17
- 52-week high
- $11.72
- 52-week low
- $0.88
- Avg volume (3M)
- —
- Shares outstanding
- 3.98M
- Employees
- 8
- Next earnings
- —
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
- ISIN
- US76135L8046
- Founded
- 2019
- Listed since
- Nov 17, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.